Development of Clinical Algorithm to Identify Risk for Alzheimer’s disease in Early Midlife

Principal Investigator
Jill Goldstein, PhD
Massachusetts General Hospital and Harvard Medical School
Boston, MA, USA
About the Research Project
Program
Award Type
Standard
Award Amount
$1,268,624
Active Dates
March 30, 2018 - September 30, 2022
Grant ID
CA2018607
Goals
This project will support the launching of a comprehensive effort (integrating clinical, physiological and brain biology traits) to identify in early midlife biomarkers for Alzheimer’s disease risk informed by sex differences in brain aging and memory decline. This is one of the first projects to comprehensively assess multiple predicted biomarkers for Alzheimer’s risk in middle age and relate them to brain scans, physiology, genetics, and clinical data with a specific focus on incorporating differences between men and women in Alzheimer’s development.
Summary
Eighteen percent of the U.S. is more than 60 years of age, with projections of rising to 25-30% by 2050. Thus, healthy aging is one of the most important public health challenges of our time. Maintaining intact cognitive function is critical to that end. Most work on cognitive aging and Alzheimer’s begins with people more than 65 years old. However, we now know that successful treatment likely should begin in early midlife. We have an unprecedented opportunity to create a “living laboratory” for the identification of biomarkers and targets for therapeutics to enhance one’s resilience to aging and prevent memory loss beginning in early midlife. We are leveraging the Partners HealthCare Biobank by creating the Healthy Aging Translational Cohort (HATCH). As part of this effort, with BrightFocus Foundation funds, we are launching the development and validation of a quantitative tool, a clinical risk algorithm, that integrates polygenic-clinical-physiological and brain phenotyping to identify in early midlife (ages 45-70 years), people who may already have accumulated amyloid pathology and are at highest risk for cognitive decline and Alzheimer’s later in life. Given this is a critical period of the menopausal transition in women, we have a specific focus on identifying the impact of ovarian decline on aging of memory circuitry and Alzheimer’s risk. Identification of sex-selective predictors of early cognitive decline may have substantial implications for development of sex-selective preventions and therapeutics.
Grants
Related Grants
Alzheimer's Disease Research
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015

Principal Investigator
Guojun Bu, PhD
Alzheimer's Disease Research
Synergistic Effects of Biological Sex and Sleep Loss in an AD Mouse Model
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Mallar Chakravarty, PhD
Synergistic Effects of Biological Sex and Sleep Loss in an AD Mouse Model
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Mallar Chakravarty, PhD
Alzheimer's Disease Research
Regulatory Mechanisms Underlying Endosomal Targeting of SORL1
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Olav Andersen, PhD
Regulatory Mechanisms Underlying Endosomal Targeting of SORL1
Active Dates
January 01, 2025 - December 31, 2026

Principal Investigator
Olav Andersen, PhD